A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Inclusion criteria

• Are on stable incretin therapy at screening
• With persistent obesity or overweight defined as:

• ≥30 kg/m2 OR
• ≥27 kg/m2 with at least one existing obesity related complication at screening:

• hypertension
• dyslipidemia
• obstructive sleep apnea
• cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure), or
• type 2 diabetes
• Have a stable body weight (<5% body weight change) at screening

Exclusion criteria

• Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
• Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
• Have type 1 diabetes
• Have taken any of the following antihyperglycemic medications within 90 days before screening:

• dipeptidyl peptidase-4 (DPP-4) inhibitors
• amylin analogs
• insulin
• Have had within 90 days prior to screening:

• heart attack
• stroke
• coronary artery revascularization
• unstable angina, or
• hospitalization due to congestive heart failure
• Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure